Abiraterone Outcomes Tied to NLR
For example, men with a baseline NLR below 2.5, patients who received abiraterone had a significant 28% decreased risk of death.
Print Issue: December 01, 2018
The Rapidly Evolving Landscape for mRCC
Incredible progress is being made in kidney cancer treatment.
Front-Line Combo Found Superior for Advanced RCC
Avelumab plus axitinib is associated with longer progression-free survival compared with sunitinib as first-line therapy in patients with advanced renal cell carcinoma.
Prostate Cancer Linked to Greater Fat, Fatty Acid Intake
As stearic acid and total fatty acid intake increased from one quintile to the next, prostate risk increased by 23% and 21%, respectively.
Prostate Cancer Focal Ablation Can Be a Reasonable Option
Patient selection and physician-patient commitment to careful follow-up surveillance are key.
‘Real-World’ Study Characterizes PCa Active Surveillance
Findings from a large contemporary cohort of men on active surveillance for prostate cancer shows that disease characteristics, not socioeconomic factors, are driving prostate cancer management.
Later-Stage RCC at Diagnosis Less Likely in Blacks
At the time of diagnosis of renal cell carcinoma, blacks had 33% lower odds of regional disease compared with whites, a new study found.
Should doctors answer calls for help in public places?
The professional obligation to promote the health and wellbeing of the members of society is central to the legitimacy and integrity of the profession.
Home Hemodialysis May Offer Better Survival
A study of new dialysis patients showed that home hemodialysis was associated with a 23% decreased risk of death at 1 year compared with in-center hemodialysis.
Novel Acid-Binding Drug Effective for Metabolic Acidosis in CKD
A polymer that binds to hydrochloric acid in the GI tract and does not enter the systemic circulation significantly improved serum bicarbonate levels compared with placebo.
Next post in Kidney Week 2018
